PG
PDLI

PEAK6 Group’s PDL BioPharma, Inc. PDLI Stock Holding History

PEAK6 Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,815
Closed -$60K – 5430
2016
Q3 		$60K Sell
17,815
-16,030
-47% -$50.9K ﹤0.01% 3812
2016
Q2 		$106K Buy
+33,845
New +$113K ﹤0.01% 3549
2015
Q4 		– Sell
-4,252
Closed -$21K – 5862
2015
Q3 		$21K Sell
4,252
-5,649
-57% -$32.4K ﹤0.01% 4875
2015
Q2 		$64K Buy
9,901
+5,946
+150% +$39.8K ﹤0.01% 4473
2015
Q1 		$28K Buy
3,955
+3,880
+5,173% +$28.1K ﹤0.01% 4434
2014
Q4 		$1K Sell
75
-13,190
-99% -$104K ﹤0.01% 4576
2014
Q3 		$99K Buy
+13,265
New +$123K ﹤0.01% 3808
2014
Q1 		– Sell
-300
Closed -$2.57K – 5942
2013
Q4 		$3K Buy
+300
New +$2.53K ﹤0.01% 4791

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PEAK6 Group's PDLI Position: Q4 2016 in Review

PEAK6 Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 17,815 shares — an estimated $60K sold.

PEAK6 Group first reported a position in PDLI in Q4 2013 and held it in 8 quarters. The position peaked at $106K in Q2 2016. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • PEAK6 Group reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • PEAK6 Group sold 17,815 PDL BioPharma, Inc. shares in Q4 2016, an estimated $60K.
  • PEAK6 Group first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 8 quarters.
  • PEAK6 Group's PDL BioPharma, Inc. position peaked at $106K in Q2 2016.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on PEAK6 Group's 13F filing for Q4 2016, filed 13 Feb 2017.